       Document 0304
 DOCN  M9640304
 TI    Combination chemotherapy (RCM protocol: response-oriented cyclic
       multidrug protocol) for the acute or lymphoma type adult T-cell
       leukemia.
 DT    9604
 AU    Uozumi K; Hanada S; Ohno N; Ishitsuka K; Shimotakahara S; Otsuka M;
       Chyuman Y; Nakahara K; Takeshita T; Kuwazuru Y; et al; Second Department
       of Internal Medicine, Faculty of Medicine,; Kagoshima University, Japan.
 SO    Leuk Lymphoma. 1995 Jul;18(3-4):317-23. Unique Identifier : AIDSLINE
       MED/96077739
 AB    43 patients with the acute or lymphoma type ATL were treated with the
       new combination chemotherapy (RCM protocol: response-oriented cyclic
       multidrug protocol) between January 1989 and December 1991. Complete
       response (CR) and partial response (PR) were achieved in 20.9% and 65.1%
       of all treated patients respectively. The median duration of survival
       was 6.0 months. The survival duration of patients with a high serum
       lactate dehydrogenase (LDH) value (> or = 1,000 unit) and/or a poor
       performance status (PS) (PS 3 or 4) were also improved but not in
       patients with a severe leukocytosis (> or = 35,000/microliters).
       Toxicity was mild (grade 1 or 2) except hematologic toxicity in 4
       patients (9.3%) and alopecia in one patient (2.3%). In spite of many
       patients with a poor PS (PS 3 or 4), our chemotherapeutic results are
       equal or superior to other previous reports. It seems that
       response-oriented chemotherapy is suitable for the ATL patients with
       poor prognostic factors. These results indicate that the RCM protocol is
       very useful as the first choice chemotherapy for the acute or lymphoma
       type ATL.
 DE    Adult  Aged  Antineoplastic Agents, Combined/ADVERSE
       EFFECTS/*THERAPEUTIC USE  Female  Human  Leukemia-Lymphoma, T-Cell,
       Acute, HTLV-I-Associated/*DRUG THERAPY/  MORTALITY  Leukemia, T-Cell,
       Acute/*DRUG THERAPY/MORTALITY  Male  Middle Age  Pilot Projects
       Prognosis  Support, Non-U.S. Gov't  Survival Rate  Treatment Outcome
       CLINICAL TRIAL  CONTROLLED CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

